- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2025 | 91 | GlobeNewswire (Europe) | January-March 2025• Net sales, which for the quarter only included royalties, amounted to 139 KSEK (156).• Net earnings were -57.8 MSEK (-2.9), as a result of unrealized exchange rate effects due to... ► Artikel lesen | |
| 02.04. | IMMUNOVIA AB: Immunovia publishes the Annual Report for 2024 | 1 | Cision News | ||
| 01.04. | IMMUNOVIA AB: The exercise period for warrants series TO 3 begins today | 2 | Cision News | ||
| 27.03. | IMMUNOVIA AB: Immunovia announces determined exercise price for warrants series TO 3 | 2 | Cision News | ||
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 161 | PR Newswire | LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 140 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic... ► Artikel lesen | |
| 21.03. | IMMUNOVIA AB: Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study | 2 | Cision News | ||
| 19.03. | Immunovia AB: Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test | 125 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation... ► Artikel lesen | |
| 03.03. | IMMUNOVIA AB: Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference | 1 | Cision News | ||
| 25.02. | Immunovia reports Q4 results | 2 | Seeking Alpha | ||
| 25.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2024 | 171 | PR Newswire | LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October- December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).
... ► Artikel lesen | |
| 21.02. | Immunovia initiates search for a new CFO | 3 | Seeking Alpha | ||
| 21.02. | IMMUNOVIA AB: Immunovia initiates search for a new CFO to support commercialization in the USA | 3 | Cision News | ||
| 21.02. | IMMUNOVIA AB: Invitation to Immunovia's Q4 presentation | 2 | Cision News | ||
| 31.01. | Change in number of shares and votes in Immunovia AB (publ) | 255 | PR Newswire | LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series... ► Artikel lesen | |
| 20.01. | Immunovia AB announces outcome of exercise of warrants series TO 2 | 335 | PR Newswire | LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January... ► Artikel lesen | |
| 08.01. | Immunovia AB (Publ) presents Nomination Committee | 249 | PR Newswire | LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.... ► Artikel lesen | |
| 02.01. | The exercise period for warrants of series TO 2 beings today: Immunovia AB | 343 | PR Newswire | LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2... ► Artikel lesen | |
| 02.01. | IMMUNOVIA AB: The exercise period for warrants of series TO 2 beings today | 2 | Cision News | ||
| 28.12.24 | Immunovia AB: Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme | 865 | PR Newswire | LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been... ► Artikel lesen |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 6,368 | -0,11 % | Teladoc Health, Inc.: Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08 | NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to two new employees. Effective June... ► Artikel lesen | |
| HIMS & HERS HEALTH | 48,990 | -0,97 % | SCHOCK bei Renk, Novo Nordisk Aktie "KAUFEN", PanGenomic Health auf den Spuren von Hims & Hers | Schock bei Renk & Co.! Gestern Nachmittag machte die Nachricht die Runde, dass die EU den Rüstungskonzernen an die Milliardengewinne gehen will. Schließlich stehen die Unternehmen vor goldenen Zeiten.... ► Artikel lesen | |
| BECTON DICKINSON | 151,90 | -0,20 % | How Is Becton, Dickinson and Company's Performance Compared to Other Medical Instruments & Supplies Stocks? | ||
| DEXCOM | 76,11 | +0,09 % | Verhaltene Kauflaune bei Dexcom-Aktie (74,6297 €) | An der US-amerikanischen Börse ist die Dexcom-Aktie zur Stunde unauffällig. Das Papier notiert aktuell bei 85,31 US-Dollar. Kaum auffällig ist derzeit am Aktienmarkt der Kurs von Dexcom. Das Wertpapier... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,800 | +8,40 % | Ascendiant Capital raises Atossa Genetics stock price target to $7.50 | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports First Quarter 2025 Financial Results and Provides Business Update | SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,157 | +3,86 % | XFRA AUFHEBUNG VON AMTS WEGEN IN NZRYME0001S4 | Folgende Geschaefte in der ISIN NZRYME0001S4, Wertpapier-Name: RYMAN HEALTHCARE GRP LTD, wurden von Amts wegen aufgehoben:Datum Zeit Volumen Preis24.02.2025 08:02:33 100 2.388 ► Artikel lesen | |
| CYTOSORBENTS | 0,884 | -4,54 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update | PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 5,240 | -100,00 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| SENSEONICS | 0,460 | -0,69 % | Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense 365 Continuous Glucose Monitoring System for People with Diabetes | ||
| STAAR SURGICAL | 15,440 | -1,53 % | STAAR Surgical auf William Blair Konferenz: Strategische Neuausrichtung | ||
| EKSO BIONICS | 0,257 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 02.06.2025 | The following instruments on XETRA do have their first trading 02.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.06.2025
Aktien
1 LU0445408270 Altisource Portfolio... ► Artikel lesen | |
| INTERPACE BIOSCIENCES | 0,650 | 0,00 % | Interpace Biosciences, Inc.: Effective May 2, 2025, Interpace Diagnostics Will No Longer Accept Specimens for PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk | Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace"... ► Artikel lesen | |
| INSPIRE MEDICAL SYSTEMS | 120,00 | +0,59 % | Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook | Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire... ► Artikel lesen | |
| SOLENO THERAPEUTICS | 65,50 | -1,21 % | SOLENO THERAPEUTICS INC - 8-K, Current Report |
IMMUNOVIA AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,005 (+23,98 %) liegt der Kurs bei 0,024 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.